Processa Pharmaceuticals regains compliance with Nasdaq minimum bid price rule

Processa Pharmaceuticals has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Market and that the matter is now closed. To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024.